PerkinElmer, a listed diagnostics solutions provider, completed the acquisition of Immunodiagnostic Systems, an in-vitro diagnostics company, for $155m. Through this acquisition, PerkinElmer will be able to grow its overall Diagnostics business and specifically its immunodiagnostics segment. Moreover, the deal will enable PerkinElmer to combine its channel expertise and testing capabilities with IDS’s best-in-class chemiluminescence products in endocrinology, autoimmunity and infectious diseases to better serve customers around the world.